Related content

Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

By Hartmann M.   Fedders M.   Schneider A.   Kath R.   Camara O.   Oelschläger H.  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 9, 2007-09 ,pp. : 619-625

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients

By                        

Oncology Reports, Vol. 30, Iss. 5, 2013-01 ,pp. : 2385-2398

Spandidos Publications

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite

First-Line Chemotherapy with Paclitaxel and Platinum for Advanced and Recurrent Cancer of the Cervix-A Phase II Study

By Piver M.S.   Ghamande S.A.   Eltabbakh G.H.   O'Neill-Coppola C.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 334-337

Elsevier

Access to resources Recommend Favorite

Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)

By Chaudhry Parvesh   Srinivasan Radhika   Patel Firuza  

Cancer Investigation, Vol. 27, Iss. 8, 2009-10 ,pp. : 877-884

Informa Healthcare

Access to resources Recommend Favorite